Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal abobotulinum toxin A plus FIOD Whitening Serum versus FIOD Whitening Serum alone for melasma (split-face trial)
TCTR20260716003Phase 2Recruiting
- Sponsor
- Chanisa Kiatsurayanon
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of abobotulinumtoxinA in melasma, sponsored by Chanisa Kiatsurayanon. Started Apr 2026; status: recruiting.
02
Drugs
abobotulinumtoxinA
03
Conditions
melasma
Beyond the preview
Go deeper on TCTR20260716003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260716003.